These and other GLP1-RA diabetes/weight-loss meds can also boost outcomes for folks battling chronic kidney disease, new ...

The Trump administration’s cuts to university research grants will make America sicker and poorer in the long run.

Compounding pharmacies aren’t the only makers of off-brand versions of Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. The ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Aptar has a narrow economic moat, with durable switching costs in the Pharma business supported by intangible assets throughout the product portfolio from expertise in product regulation, design, and ...

At medical conferences and hospital cafeterias, one thing has become increasingly clear—many doctors are using Ozempic, ...

US bakery major Flowers Foods has blamed ongoing bread category weakness and changing consumer preferences for ...

A human-derived, ultra-long-acting GLP-1 injection independently researched and developed by Innogen, a Shanghai-based ...

Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

A small percentage of patients taking the extraordinarily popular GLP-1 medications have experienced vision problems, but a ...

Add surgical tweaks to fix so-called "Ozempic face" to the list of top trending cosmetic procedures, as tallied by the ...